Aastrom falls on RESTORE-CLI data

Aastrom Biosciences Inc. (NASDAQ:ASTM) fell $1.49 (36%) to $2.71 on Thursday after ixmyelocel-T (expanded autologous mixed cell therapy) met the primary endpoint vs. placebo in the Phase IIb RESTORE-C...